A Phase 2 interventional study of ATH434 in Multiple System Atrophy, sponsored by Alterity Therapeutics. Enrolling by invitation at 4 sites in France. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Alterity Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Multiple System Atrophy with a site in France — 6 open to participants now, 8 under way, 1 of them phase 3. Multiple System Atrophy · France.
Among the 32 studies in Multiple System Atrophy with a site in France, this one is the 27th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 9 in phase 2, and was the 32nd registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →6 of the 32 studies in Multiple System Atrophy with a site in France are open now. Recruiting first, the newest first:
Teva Branded Pharmaceutical Products R&D LLC · Sites in France, United States, Germany and 4 more countries
Ages 30+
Ionis Pharmaceuticals, Inc. · Sites in France, Austria, Germany and 2 more countries
Ages 40–70
University Hospital, Bordeaux · Sites in France
Ages 30+ · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 4
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7 is below the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 77 across the 27 interventional studies, 100 across the 5 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
Alterity Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Alterity Therapeutics has 4 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Multiple System Atrophy with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04165486Ionis Pharmaceuticals, Inc.Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | 2027-09 |
| NCT06568237Teva Branded Pharmaceutical Products R&D LLCA Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | 2027-09-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Multiple System Atrophy with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
This is a multicenter, open-label extension (OLE) study designed to provide continued access to the investigational product ATH434 for eligible participants with Multiple System Atrophy (MSA) who have successfully completed the prior Phase 2 clinical trial (ATH434-201) in France. Up to 5 participants will be enrolled. No new participants will be recruited or enrolled in this study.
The primary objective is to monitor long-term safety, tolerability, and clinical response. Eligible participants will receive ATH434 at a dose of 75 mg twice daily (BID) to be taken with food.
The study is divided into two operational phases:
Initial Treatment Phase: Participants will receive treatment for a planned duration of 12 months.
Extension Phase: Participants may continue treatment beyond the initial 12 months based on the investigator's clinical judgment of ongoing benefit, safety, and tolerability. Continued eligibility will be re-evaluated and documented every 3 months.
Participants will undergo a combination of in-clinic and remote visits to perform safety monitoring, clinical evaluations, and investigational product accountability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who completed the prior ATH434-201 Phase 2 trial will receive ATH434 75 mg orally twice daily (BID). Treatment consists of an initial 12-month treatment phase, followed by an ongoing extension phase based on investigator assessment of continued clinical benefit, safety, and tolerability
Drug: ATH434
ATH434 75 mg tablets administered orally twice daily (BID).
Also known as: PBT434
Incidence, Severity, and Relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs)
All AEs will be reviewed at every participant contact and documented in the CRF. All SAEs will be reported within 24 hours of awareness in accordance with local regulatory requirements.
Time frame: Baseline to completion of study treatment, an average of 1 year.
Change From Baseline in Clinical Laboratory Parameters
Clinical laboratory parameters include hematology and blood chemistry panels.
Time frame: Baseline to completion of study treatment, an average of 1 year.
Change From Baseline in Vital Signs
Vital signs include blood pressure, pulse, temperature, and respiration rate.
Time frame: Baseline to completion of study treatment, an average of 1 year.
Duration of Exposure to ATH434
Total duration of treatment with investigational product per participant.
Time frame: Baseline to completion of study treatment, an average of 1 year.
Cumulative Dose of ATH434
Total cumulative dose of investigational product administered per participant.
Time frame: Baseline to completion of study treatment, an average of 1 year.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jul 2029, 33 months after the start.
Of 19 phase 2 interventional studies under Multiple System Atrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 32. This study's planned 33 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ATH434
Alterity Therapeutics